Canada: Supreme Court Clarifies Patent Doctrine of Sound Predictions

Last Updated: March 13 2003

Richard Naiberg (Partner) and Isabelle Roy (Articling Student)

On December 5, 2002, the Supreme Court of Canada delivered its reasons in Apotex Inc. et al. v. The Wellcome Foundation Ltd. et al., a case involving the validity of a patent claiming the compound AZT for use in the treatment and prophylaxis of HIV in human beings. This case raised the question of whether a valid patent can issue for an "invention" that is a mere speculation or guess at the time it is made. In its decision, the Court confirmed that the utility of a patentable invention must either be known at the time the patent application is first filed (e.g. by constructing the invention and observing its utility) or be soundly predictable in the then state of the art. Mere speculations or guesses, no matter how prophetic, are not patentable even if they turn out to have been correct.

The ruling marked the end of a lengthy legal battle. In 1983, scientists at the U.S. National Institutes of Health (NIH) learned that AIDS was caused by infection with a new retrovirus then known as HTLV-III (HIV) and began designing the assay systems necessary to test potential anti-HIV compounds In 1984, scientists at Wellcome began a similar effort, but chose to construct assays involving mouse cells and mouse retroviruses. The Wellcome scientists were not equipped to work with human cells or HIV. In the fall of 1984, the Wellcome scientists identified AZT as a compound effective to eradicate the murine retroviruses from the mouse cells in the lab dish. While these results were considered encouraging, their actual relevance to HIV treatment was unknown. HIV did not infect mouse cells and was far more complex and mutable than the murine retroviruses. In addition, the conditions of the laboratory were very different from those in a living human being where any potential HIV treatment would need to be ingested, absorbed, metabolized, and delivered to the specific human T-cells that are the target of HIV. Though the scientists at Wellcome were hopeful that AZT would be effective against HIV in a living human being, they recognized that it was impossible to predict human response from their murine results.

By the fall of 1984, NIH and Wellcome were cooperating to find anti-HIV drugs. Wellcome was sending its promising compounds to NIH and NIH scientists would examine the compounds in the human HIV assays they were continually developing and improving. Wellcome sent NIH some AZT under code.

Before any results from NIH were received, Wellcome prepared a draft patent application claiming AZT for use in treating HIV. At this point, this utility was a mere guess. In mid-February, AZT was found by NIH to effectively inhibit the replication of HIV in human cells in the laboratory. However, it was still unknown whether AZT would survive ingestion and metabolism and serve as a functioning drug. On March 16, 1985, Wellcome filed a patent application in the United Kingdom from which the Canadian patent claimed priority.

Confirming the existence of the doctrine of sound prediction in Canada, the Supreme Court ruled that utility of a patent must be established by the inventor at the date of the priorty patent application, either by demonstration or by sound prediction. Sound prediction exists when three factors are combined. First, there must be a factual basis for the prediction. Secondly, there must be an "articulable and 'sound' line of reasoning" linking the facts to the prediction. Finally, the Court states that, in order for sound prediction to establish the utility of an invention, there must be proper disclosure.

The soundness of a prediction will be a question of fact to be determined on the facts of each case. It must not, in any case, be diluted to "a lucky guess or mere speculation". To be fair to the public, there must be more than speculation. Conversely, to be fair to the inventor, absolute certainty should not be required in all cases. The doctrine of sound prediction is an attempt to strike a balance between both interests. The Court nonetheless cautioned that, since sound prediction is not tantamount to certainty, there will always exist a risk that the prediction will not materialize. Should that occur, the Court added, the patent could then be invalidated for want of utility.

Reinstating the facts as found by the trial judge, the Supreme Court found that Wellcome had no invention before it received NIH's results. The statements contained in the draft patent application constituted mere unpatentable speculation. However, with the NIH results in hand, the Court held that Wellcome had sufficient information to form a sound prediction. As a result, the patent was not invalidated as related to a mere speculation.

The appellants also argued that if the invention was not complete without the input of the NIH scientists, then the NIH scientists must be joint inventors of the invention and Wellcome's failure to name the NIH scientists as joint inventors invalidated the Canadian patent. The Court disagreed with this approach on the basis that the conception of the use of AZT to treat HIV infection arose only in the minds of the Wellcome scientists, and the not the minds of the NIH scientists. Without contributing to the conception, the NIH scientists could not be considered joint inventors.

Further, in a novel reading of subsection 53(1) of the Patent Act, the Court found that a failure to name joint inventors would not invalidate a patent unless there had been wilful intention on the part of Wellcome to mislead the Patent Office, a fact not found on the evidence.

As a result, the validity of the AZT patent was upheld.

This Update is intended to provide general comment only and should not be relied upon as legal advice.

© Goodmans LLP, 2003.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions